Korea Exchange · Healthcare
Daewoong pharmaceutical stock from India: price, numbers and tax
Daewoong pharmaceutical (069620) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Daewoong pharmaceutical at a glance
- Price
- ₩108,500.00-₩1,900.00 (1.72%)
- Market cap
- ₩1.25T
- Day range
- ₩107,400.00 – ₩110,600.00
- P/E
- 6.39
- Dividend yield
- 0.55%
- Volume
- 31.87K
- 1 month
- -5.16%
- 6 months
- -26.44%
- YTD
- -37.03%
- 1 year
- -17.99%
- 5 years
- -19.93%
Daewoong pharmaceutical statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩1.6T | ₩1.4T | ₩1.4T | ₩1.3T | ₩1.2T |
| Gross profit | ₩812.9B | ₩734.2B | ₩687.1B | ₩639.0B | ₩544.7B |
| Operating income | ₩195.5B | ₩147.9B | ₩121.1B | ₩95.8B | ₩88.7B |
| Net income | ₩195.9B | ₩24.7B | ₩121.7B | ₩42.2B | ₩24.5B |
| Earnings per share | ₩17,021.00 | ₩2,149.85 | ₩10,656.00 | ₩3,815.95 | ₩2,226.87 |
| EBITDA | ₩245.8B | ₩112.5B | ₩164.9B | ₩86.8B | ₩129.6B |
| Total assets | ₩2.4T | ₩2.0T | ₩1.8T | ₩1.6T | ₩1.4T |
| Total debt | ₩829.4B | ₩649.2B | ₩469.7B | ₩446.7B | ₩445.7B |
| Cash and short-term investments | ₩172.8B | ₩116.3B | ₩137.7B | ₩140.7B | ₩173.7B |
| Shareholders' equity | ₩1.0T | ₩794.6B | ₩767.3B | ₩608.0B | ₩573.6B |
| Operating cash flow | ₩149.2B | ₩51.5B | ₩136.0B | ₩118.2B | ₩40.0B |
| Free cash flow | −₩42.3B | −₩177.5B | ₩26.7B | ₩4.9B | −₩34.8B |
| Capital expenditure | −₩191.5B | −₩229.0B | −₩109.3B | −₩113.3B | −₩74.8B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Yuhan | 000100.KS | ₩73,100.00 | ₩5.38T |
| Daewoong | 003090.KS | ₩15,690.00 | ₩659.56B |
| Dong-A Socio | 000640.KS | ₩93,000.00 | ₩626.13B |
| JW Pharmaceutical | 001060.KS | ₩26,350.00 | ₩608.52B |
| Ildong Pharmaceutical | 249420.KS | ₩14,020.00 | ₩441.74B |
| Kwang Dong Pharmaceutical | 009290.KS | ₩6,920.00 | ₩343.65B |
| Huons Global | 084110.KQ | ₩23,100.00 | ₩281.96B |
| Huons | 243070.KQ | ₩19,000.00 | ₩221.38B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Daewoong pharmaceutical from India
What Daewoong pharmaceutical does
Established in 1945 and headquartered in Seoul, South Korea, Daewoong Pharmaceutical Co., Ltd. is a global entity dedicated to the research, production, and international distribution of a diverse range of pharmaceutical products. Its extensive portfolio provides therapeutic solutions across numerous health disciplines, including treatments for central nervous system disorders, endocrine conditions, musculoskeletal ailments, nephrological issues, oncology, cardiovascular diseases, gastrointestinal complaints, and metabolic dysfunctions. Daewoong pharmaceutical operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Daewoong pharmaceutical shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.